ProRetina Therapeutics, GP Pharm and BCN Peptides form a consortium for the development of innovative therapies in the eye field
May 20, 2011
ProRetina, spin-off of Biological Investigation Center (CSIC), GP Pharm Biopharmaceutical and BCN Peptides, fine chemicals division of Lipotec Group, have agreed to form a consortium to deal with the development of formulations that allow drugs to vehicular to the retina. The union aims to improve quality of patient’s life through the treatment of eye diseases such as retinitis pigmentosa and other retinal dystrophies. Download full Press Release

European Consortium for the Early Treatment of Diabetic Retinopathy
April 28, 2011
BCN Peptides is one of the Key Partners of the European Consortium for the Early Treatment of Diabetic Retinopathy. The Project has been positively evaluated by the European Commission and have proceed to negotiations for a Grant Agreement.

BCN PEPTIDES and DIVERDRUGS announce results of DD04107, a new class of non-opioid analgesics
October 28, 2010
Barcelona, October, 2010 – BCN Peptides and DiverDrugs, two biopharmaceutical companies specialized in peptides, announced positive preclinical results of their candidate for cancer pain, chronic pain and other inflammatory pain conditions and their intention to conduct Phase I clinical trials. Download full Press Release

Japanese MHLW. Accreditation as Foreign Manufacturer
July 30, 2010
On July 2010, BCN Peptides has received the Accreditation as Foreing Drug Manufacturer from Japanese MHLW. 

Pharmaceutical Laboratory for Quality Control of Final Product
April 15, 2010
Since March 2010, BCN Peptides has been authorised by the Spanish Health Authorities to work as Pharmaceutical Laboratory for the analysis of Final Pharmaceutical Product. With this License we can offer to our customers the possibility to perform the Analytical development, validations and tests both for the release and for the stability Studies of Final Pharmaceutical Product.

US FDA Audit
March 19, 2010
We are proud to communicate, that after a four days audit (15th-18th March), BCN Peptides has been approved by US FDA for the GMP Manufacture of Peptides, following ICH Q7. Let us remark that this is our second US FDA audit, first approval was in November 2006, but this is our first US FDA audit in our New Manufacturing Site located in Sant Quintí de Mediona (Barcelona, Spain). This site is a state of the art facility for the manufacture of API peptides using Solid Phase Synthesis technology.

Two New CEPs for BCN Peptides: Buserlin and Goserelin
April 17, 2009
BCN Peptides has received two new CEPs from the European Pharmacopoeia for Buserelin and Goserelin. Today the company holds a total of 6 CEPs for Salmon Calcitonin, Leuprolide, Somatostatin, Desmopressin, Buserelin and Goserelin.

New Manufacturing Site
July 31, 2008
BCN Peptides has built a brand new custom-design facility that allows us to manufacture multi kilo batches of GMP Peptide using SPPS technology. Also this site is designed to be able to manufacture sterile grade peptides. We encourage you come to Barcelona and visit the best site for the SPPS of peptides.